Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CUMBERLAND PHARMACEUTICALS INC.

(CPIX)
  Report
Delayed Nasdaq  -  03:59 2022-12-02 pm EST
2.250 USD   -2.17%
11/14CUMBERLAND PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
11/08Cumberland : Q3 Earnings Snapshot
AQ
11/08Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.10
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cumberland Pharmaceuticals : Emerging Technologies Names Van Tucker to Board of Directors

03/15/2021 | 11:08am EST

CUMBERLAND EMERGING TECHNOLOGIES

NAMES VAN TUCKER TO BOARD OF DIRECTORS

NASHVILLE, Tenn. (March 15, 2021) - Cumberland Emerging Technologies, Inc. (CET) announced today the addition of Van Tucker to its board of directors. The mission of CET is to develop innovative new biomedical products emerging from university-based research. CET also manages Nashville's Life Sciences Center which supports a growing number of biomedical startups and successful graduates.

Tucker is president and CEO of Launch Tennessee (LaunchTN), a public-private partnership with a vision to make Tennessee the most startup-friendly state in the nation. LaunchTN provides startup resources to entrepreneurs, including capital sources, mentorship, accelerators, entrepreneurship training and more.

"We are pleased to welcome Van to our CET board of directors," said A.J. Kazimi, CEO of CET and Cumberland Pharmaceuticals. "Her work in the Nashville community and her startup experience will bring valuable benefits to our organization as we continue to work with early-stage life science discoveries."

Tucker started her career in the banking and finance industry, having served as senior vice president of both Bank of America's entertainment industry group and Regions' private banking sector. Following her time with Regions, she was involved in the founding of Avenue Bank, a startup community bank in Nashville, where she served as chief creative officer. Prior to joining LaunchTN, Tucker was founder and CEO of the Nashville Fashion Alliance, an organization that raised international awareness of the $6 billion impact of the fashion industry on the local economy. She has also served as the founding leader of two private strategy consulting companies serving Fortune 100 companies.

Tucker has been named to the Nashville Business Journal's "Women of Influence" list and Forbes' list of "40 Over 40 Women To Watch." In addition to CET, she has served on a variety of private and community boards, including Americana Music Association, Leadership Music, Nashville Symphony Orchestra, Vanderbilt Children's Hospital and the Owen Graduate School of Management Alumni Board.

CET's board of directors also includes Kazimi; Alan Bentley, assistant vice chancellor of technology transfer at Vanderbilt University; Kenneth J. Holroyd, vice president of technology transfer at Vanderbilt University Medical Center; John A. Smith, professor of pathology at the University of Alabama at Birmingham School of Medicine; James P. Leyda, former senior executive of Hoechst Marion Roussel (now Aventis); and Samuel M. Lawrence, CEO and co-founder of CytoViva, Inc.

About Cumberland Emerging Technologies:

Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.

Disclaimer

Cumberland Pharmaceuticals Inc. published this content on 15 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 March 2021 16:07:08 UTC.


ę Publicnow 2021
All news about CUMBERLAND PHARMACEUTICALS INC.
11/14CUMBERLAND PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condi..
AQ
11/08Cumberland : Q3 Earnings Snapshot
AQ
11/08Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.10
MT
11/08Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Posts Q3 Revenue $11.4M
MT
11/08Cumberland Pharmaceuticals Seeks Acquisitions
CI
11/08Transcript : Cumberland Pharmaceuticals Inc., Q3 2022 Earnings Call, Nov 08, ..
CI
11/08Cumberland Pharmaceuticals Reports 41% Revenue Growth
PR
11/08Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
11/08Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on Ma..
CI
11/01Cumberland pharmaceuticals to announce third quarter 2022 financial results
PR
More news
Financials (USD)
Sales 2021 36,0 M - -
Net income 2021 -3,51 M - -
Net cash 2021 11,0 M - -
P/E ratio 2021 -19,8x
Yield 2021 -
Capitalization 32,5 M 32,5 M -
EV / Sales 2020 0,98x
EV / Sales 2021 1,61x
Nbr of Employees 83
Free-Float 54,7%
Chart CUMBERLAND PHARMACEUTICALS INC.
Duration : Period :
Cumberland Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUMBERLAND PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Managers and Directors
A. J. Kazimi Chairman & Chief Executive Officer
John M. Hamm Chief Financial & Accounting Officer
James L. Herman Chief Compliance Officer & Senior Vice President
Gordon R. Bernard Independent Director
James R. Jones Independent Director